Logo image of XFOR

X4 PHARMACEUTICALS INC (XFOR) Stock Fundamental Analysis

NASDAQ:XFOR - Nasdaq - US98420X1037 - Common Stock - Currency: USD

1.86  -0.04 (-2.11%)

Premarket: 1.95 +0.09 (+4.84%)

Fundamental Rating

2

Overall XFOR gets a fundamental rating of 2 out of 10. We evaluated XFOR against 555 industry peers in the Biotechnology industry. XFOR may be in some trouble as it scores bad on both profitability and health. XFOR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

XFOR had negative earnings in the past year.
XFOR had a negative operating cash flow in the past year.
In the past 5 years XFOR always reported negative net income.
In the past 5 years XFOR always reported negative operating cash flow.
XFOR Yearly Net Income VS EBIT VS OCF VS FCFXFOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of 11.23%, XFOR belongs to the top of the industry, outperforming 94.77% of the companies in the same industry.
The Return On Equity of XFOR (63.62%) is better than 98.92% of its industry peers.
Industry RankSector Rank
ROA 11.23%
ROE 63.62%
ROIC N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
XFOR Yearly ROA, ROE, ROICXFOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Profit Margin of XFOR (46.54%) is better than 99.10% of its industry peers.
Looking at the Gross Margin, with a value of 82.42%, XFOR belongs to the top of the industry, outperforming 86.67% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 46.54%
GM 82.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XFOR Yearly Profit, Operating, Gross MarginsXFOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

XFOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XFOR has been increased compared to 1 year ago.
XFOR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XFOR is higher compared to a year ago.
XFOR Yearly Shares OutstandingXFOR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XFOR Yearly Total Debt VS Total AssetsXFOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

XFOR has an Altman-Z score of -7.48. This is a bad value and indicates that XFOR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.48, XFOR is not doing good in the industry: 68.65% of the companies in the same industry are doing better.
A Debt/Equity ratio of 3.30 is on the high side and indicates that XFOR has dependencies on debt financing.
XFOR has a worse Debt to Equity ratio (3.30) than 82.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.3
Debt/FCF N/A
Altman-Z -7.48
ROIC/WACCN/A
WACC10.34%
XFOR Yearly LT Debt VS Equity VS FCFXFOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

XFOR has a Current Ratio of 3.70. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of XFOR (3.70) is comparable to the rest of the industry.
XFOR has a Quick Ratio of 3.58. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.
XFOR's Quick ratio of 3.58 is in line compared to the rest of the industry. XFOR outperforms 43.06% of its industry peers.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.58
XFOR Yearly Current Assets VS Current LiabilitesXFOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

XFOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.90%, which is quite impressive.
EPS 1Y (TTM)35.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, XFOR will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.05% on average per year.
The Revenue is expected to grow by 145.58% on average over the next years. This is a very strong growth
EPS Next Y47.35%
EPS Next 2Y25.71%
EPS Next 3Y22.96%
EPS Next 5Y14.05%
Revenue Next Year1281.59%
Revenue Next 2Y240.14%
Revenue Next 3Y271.98%
Revenue Next 5Y145.58%

3.3 Evolution

XFOR Yearly Revenue VS EstimatesXFOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
XFOR Yearly EPS VS EstimatesXFOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XFOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XFOR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XFOR Price Earnings VS Forward Price EarningsXFOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XFOR Per share dataXFOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15 -20

4.3 Compensation for Growth

XFOR's earnings are expected to grow with 22.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.71%
EPS Next 3Y22.96%

More info and screens

0

5. Dividend

5.1 Amount

XFOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (7/1/2025, 9:17:26 PM)

Premarket: 1.95 +0.09 (+4.84%)

1.86

-0.04 (-2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners51.93%
Inst Owner Change6.6%
Ins Owners2.45%
Ins Owner Change75.76%
Market Cap10.77M
Analysts83.64
Price Target43.52 (2239.78%)
Short Float %9.06%
Short Ratio1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.42%
Min EPS beat(2)-12.04%
Max EPS beat(2)100.88%
EPS beat(4)1
Avg EPS beat(4)-303.78%
Min EPS beat(4)-1301.88%
Max EPS beat(4)100.88%
EPS beat(8)3
Avg EPS beat(8)-155.06%
EPS beat(12)6
Avg EPS beat(12)-100.65%
EPS beat(16)7
Avg EPS beat(16)-78.4%
Revenue beat(2)2
Avg Revenue beat(2)674.26%
Min Revenue beat(2)35.03%
Max Revenue beat(2)1313.49%
Revenue beat(4)3
Avg Revenue beat(4)344.75%
Min Revenue beat(4)-67.57%
Max Revenue beat(4)1313.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.93%
PT rev (3m)1342.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3568.21%
EPS NY rev (1m)0.1%
EPS NY rev (3m)-2084.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-45.23%
Revenue NY rev (1m)18.77%
Revenue NY rev (3m)142.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.46
EYN/A
EPS(NY)-8.94
Fwd EYN/A
FCF(TTM)-20.71
FCFYN/A
OCF(TTM)-18.94
OCFYN/A
SpS5.42
BVpS3.96
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.23%
ROE 63.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 46.54%
GM 82.42%
FCFM N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 3.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 848.51%
Cap/Sales 32.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.58
Altman-Z -7.48
F-Score4
WACC10.34%
ROIC/WACCN/A
Cap/Depr(3y)318.09%
Cap/Depr(5y)293.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.51%
EPS Next Y47.35%
EPS Next 2Y25.71%
EPS Next 3Y22.96%
EPS Next 5Y14.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1281.59%
Revenue Next 2Y240.14%
Revenue Next 3Y271.98%
Revenue Next 5Y145.58%
EBIT growth 1Y1.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.53%
OCF growth 3YN/A
OCF growth 5YN/A